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Background. Tolerance towards the effects of benzodiazepines is observed in various animal and 
human studies. Therefore, it is assumed that patients who use benzodiazepines for a longer period 
of time need to increase their dose over time to experience the same effect.
Objective. To observe whether long-term benzodiazepine users increase their dose over time.
Methods. From the Dutch National Information Network of Family Practices, a group of long-term 
benzodiazepine users was identified. This group was divided into an incident long-term benzodi-
azepine users group (N = 113) and a prevalent long-term benzodiazepine users group (N = 992). 
Long-term use of benzodiazepines was defined as usage for at least 6 months. The main outcome 
was a change in prescribed dose from baseline until 24 months after baseline. Linear regression 
analysis was performed to evaluate dose change.
Results. Neither incident long-term benzodiazepine users nor prevalent long-term benzodiazepine 
users were prescribed increasing dosages during follow-up.
Conclusion.  There is no increase in prescribed dose among long-term users, as might be expected 
due to the development of tolerance to the effects of benzodiazepines.
Keywords. Anxiety/anxiety disorder, clinical research, longitudinal, primary care, psychiatry, 
sleep disorders, substance abuse (not tobacco).
Introduction
Worldwide, benzodiazepines are the most frequently 
used classes of drugs. In the Netherlands, physicians 
provide ~11 million prescriptions annually.1 Primary 
indications for benzodiazepines are anxiety and insom-
nia, but they are also used as anticonvulsants, muscle 
relaxants or pre-anaesthetic sedatives and to reduce 
symptoms of alcohol withdrawal. Whether a specific 
benzodiazepine is prescribed for the treatment of sleep 
or anxiety disorders is largely determined by differ-
ences in its pharmacokinetic profile.2,3 In anxiety or 
insomnia, benzodiazepines are the preferred agents 
only for a short period of time. It is recommended that 
they should not be used for >4 weeks and only at the 
lowest dose necessary. Nevertheless, long-term benzo-
diazepine use is still highly prevalent in Western com-
munities. Depending on the definition for ‘long-term 
benzodiazepine users’, the prevalence rates of long-
term benzodiazepine use in the general population 
vary between 1% (daily use for at least 1 year) and 3% 
(use for >90 days a year).4 Concerning the definitions, 
most articles refer to ‘long-term users’ as subjects who 
have been taking benzodiazepines for at least 1 year,5,6 
6 months4 or 3 months.1,7–9
Benzodiazepine use has many side effects and the 
efficacy of long-term treatment has not been established.4 
Therefore, long-term use of benzodiazepines should 
be severely restricted. An important issue in long-term 
benzodiazepine use is dependence and withdrawal. 
One-third of the long-term (>6 months) benzodiazepine 
users experience symptoms of withdrawal (e.g. anxiety, 
insomnia, muscle spasms and tension). Withdrawal 
symptoms are responsible for continuation of use when 
subjects interpret them as return of original symptoms. 
Furthermore, benzodiazepines are widely abused, in the 
context of recreational and illicit use, with associated risks 
(due to interactions with other drugs or intravenous use) 
such as viral infection and local tissue necrosis.10 Another 
important issue is the development of tolerance.2,5
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‘Drug tolerance’ is defined as the process by which 
the effects of the same dose of a drug decrease with 
repeated administration, resulting in the need to 
increase the dose to experience the same effect.3 In 
insomnia, tolerance towards the sedative effect of ben-
zodiazepines has been widely reported in both animals 
and humans. Time to the development of tolerance 
towards the sedative effects of benzodiazepines dif-
fers between the different types of benzodiazepines. 
Tolerance develops faster for benzodiazepines with 
a shorter half-life than for those with longer half-life 
periods.2,3,9,11–13 Tolerance towards the anxiolytic effects 
has been shown inconsistently in various animal and 
human studies, and when detected, it appears to occur 
at a slower rate and to a lesser extent than sedative 
tolerance.2,14–16 There are many receptors known to be 
involved in the development of tolerance, but the exact 
mechanisms responsible for it have not been entirely 
elucidated.2,12 The development of tolerance towards 
the effects of benzodiazepines raises the expectation 
that long-term benzodiazepine users have to increase 
their dose over time to experience the same effect. 
A  retrospective study among American long-term 
benzodiazepine recipients conducted in 2003 showed 
no increase in benzodiazepine dosages over time.17 In 
this study, the prescribed daily dose (PDD) was used to 
evaluate dose increase, where 10 mg of diazepam was 
1 PDD. The incidence of escalation to a higher dosage 
was 1.6%. However, dosage escalation was defined as 
a very substantial increase of 2 PDD for elderly or 4 
PDD for younger subjects. Subjects using antidepres-
sants or who filled duplicate prescriptions had a higher 
chance of dosage escalation.17 The Dutch Health Care 
system is organized differently than the health care 
system in the USA. In the Netherlands, >90% of the 
repeat prescriptions for benzodiazepines are issued by 
the family physician. Within a registration network of 
family practices, we were able to investigate whether 
long-term benzodiazepine users in Dutch primary care 
increase their dosage over time.
Methods
Study population
The source population consisted of the subjects of the 
control group of a large benzodiazepine reduction 
study in family practice (the Benzoredux study, 
executed from 1998 to 2001).7,8 This natural course 
control group consisted of long-term benzodiazepine 
users from 19 family practices, selected from the 
Dutch National Information Network of Family 
Practices.18 Subjects were included in the Benzoredux 
study if they had been prescribed benzodiazepines 
for >3 months, with a prescribed amount enough for 
60 days of use according to the prescription rules of 
the family practitioner. During the observation period 
of 2.5 years, patients and practitioners in the control 
group were unaware of their prescription data being 
observed. Long-term benzodiazepine users who had 
received prescriptions of benzodiazepines for daily 
use within the first 6  months of the observation 
period were selected for the present study. These 
6 months were defined as the baseline period for the 
present study.
The prescription data of benzodiazepines for the 6-
month period before the baseline of the current study 
were used to distinguish two subgroups: the incident 
long-term benzodiazepine users group and the preva-
lent long-term benzodiazepine users group. The inci-
dent long-term users (N = 113) were defined as subjects 
who did not receive any prescription of benzodiaz-
epines in the 6-month period prior to baseline. After 
this prescription-free period, this group received pre-
scriptions for benzodiazepines for at least 6 months. 
These subjects, therefore, were defined as new long-
term benzodiazepine users, further called ‘incident 
long-term benzodiazepine users’. In this group, we 
could observe the pattern of use during the first 2 years 
of benzodiazepine use. The prevalent long-term users 
group (N = 992) contained subjects who received pre-
scriptions for benzodiazepines in the 6 months prior to 
baseline and who continued the use of benzodiazepines 
for at least 6 months after this period. Because they had 
already used benzodiazepines in the 6-month observa-
tion period, they were called prevalent long-term ben-
zodiazepine users.
Measurements and end points
Prescriptions for benzodiazepines [anatomical thera-
peutical codes (ATC)19: N05BA, N05CD and N03AE01] 
were extracted from the family practitioner’s electronic 
medical dossier and converted into diazepam equiva-
lents.20 The number of PDDs was calculated per 3-
month period, where 10 mg of diazepam was 1 PDD. 
We defined the number of PDDs for the first 3-month 
period after the baseline as the initial dose. The follow-
up period consisted of a total of eight 3-month periods. 
The primary end point was the change in the mean 
number of PDDs per 3-month period. This was calcu-
lated for the incident long-term benzodiazepine users 
and the prevalent long-term benzodiazepine users.
The secondary end point was the difference in sub-
ject characteristics and prescribed benzodiazepine 
dose changes between patients using normal and those 
using high benzodiazepine doses in both the incident 
long-term users and the prevalent long-term users. 
Patients using high benzodiazepine doses were defined 
as subjects with a prescription, in the first 3  months 
after baseline, of ≥180 PDDs (N = 1 in the incident 
long-term benzodiazepine users group and N = 105 in 
the prevalent long-term benzodiazepine users group). 
Patients with a prescription of <180 PDDs in the first 
 Follow-up of long-term benzodiazepine users 405
 by guest on M
ay 23, 2016
http://fam
pra.oxfordjournals.org/
D
ow
nloaded from
 
3-month period were considered to be normal-dose 
users (Figure 1).
This cut-off point of 180 PDDs in a 3-month period, 
meaning 2 PDDs per day, was chosen for two reasons. 
First, this clearly marks a higher dose in family prac-
tices in the Netherlands, where the majority of benzo-
diazepine users use an average of ≤1 defined daily dose 
(DDD). Second, in the Benzoredux study, the minimal 
intervention with a discontinuation letter by the family 
practitioner appeared to be only effective for subjects 
using <2 DDD. A dosage of ≥2 PDDs thus indicated a 
severer dependence profile, with a very low chance of 
decrease of use in natural course.21
The following independent variables were analysed: 
(i) age (years); (ii) gender (%  female); (iii) ATC cat-
egory: N05BA (anxiolytic) or N05CD (hypnotic), 
whereby the use of N03AE01 (clonazepam) was 
included in the anxiolytics group; (iv) type of benzo-
diazepine used; (v) half-life period of the specific ben-
zodiazepine or its main metabolites (<24 hours or ≥24 
hours); (vi) prescription of an antidepressant (measured 
in the 6- to 9-month period after baseline); and (vii) 
mean PDDs in each of the subsequent eight 3-month 
periods of the 2-year follow-up.
Statistical analysis
Statistical comparisons were performed within the 
total group of benzodiazepine users, as well as in the 
incident and prevalent long-term benzodiazepine 
users separately. Patients who were lost to follow-
up or who quitted the use of benzodiazepines at 
any time in the observation period were excluded 
from the analysis for the incident long-term benzo-
diazepine users group (N = 57) and for the preva-
lent long-term benzodiazepine users group (N = 185; 
Fig. 1). Differences in the 3-month mean PDDs were 
analysed among those who completed the study from 
within the total group of benzodiazepine users (N = 
863), the incident long-term benzodiazepine users 
group (N = 56), and the prevalent long-term benzo-
diazepine users group (N = 807; Fig. 1) using linear 
regression analysis. Differences in subjects’ charac-
teristics and prescribed benzodiazepine dose changes 
between patients using normal and those using high 
benzodiazepine doses were only calculated for the 
prevalent long-term users group. In the incident 
long-term users group, only one patient was defined 
as a high benzodiazepine dose user and was there-
fore not entered in the analysis (Fig. 1). Differences 
in proportions between normal- and high-dose users 
were analysed with chi-square tests. Analysis of con-
tinuous data was performed with Student t-tests. 
A two-sided significance level of 5% was used in all 
analyses. For the analysis, SPSS package, version 18, 
was used.22
Results
Comparisons of study subjects
No clinically significant differences in characteristics 
between the incident long-term users and the prevalent 
Figure 1 Flow diagram of study.
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long-term users were observed, except in mean age, 
which was almost 4 years lower in the incident long-
term users (Table 1).
Change in benzodiazepine dose
The mean prescribed dose in PDD per 3-month 
period in the relevant subgroups are shown in Table 2. 
Linear regression analyses were performed for the 
total group of benzodiazepine users, the incident long-
term users group and the prevalent long-term users 
group to establish whether there was an increase in 
prescribed dose over time in any of the three groups. 
The regression coefficient (increase in PDD per month) 
was 0.034 (SEM: 0.148, P = 0.817) for the total group of 
benzodiazepine users and 0.639 (SEM: 0.543, P = 0.240) 
and −0.008 (SEM: 0.153, P = 0.960) for the incident 
long-term users group and the prevalent long-term 
users group, respectively (Table 3). In addition, linear 
regression analysis showed no statistically significant 
increases in prescribed dosages for the subgroups 
of females only, males only, subjects aged <50  years, 
50–75 years, >75 years, anxiolytics users only, hypnotics 
users only, combination users only and patients who 
used antidepressants.
Users of normal and high benzodiazepine doses
In Table 4, the characteristics of subjects using normal 
and high benzodiazepine doses are shown for the prev-
alent long-term benzodiazepine users group. There is a 
significant difference in age, whereby high-dose users 
are younger (P < 0.01). Patients using normal doses 
relatively more frequently used hypnotics (33.3%) 
compared with patients using high doses (21.0%,P 
= 0.01) and high-dose users more frequently used a 
combination of benzodiazepines (P < 0.001). None of 
the high-dose users used temazepam as a single agent 
(P < 0.001). There was a significant difference in anti-
depressant use. In patients using high doses, 30.5% 
used antidepressants together with benzodiazepines 
(P < 0.001). In linear regression analysis, no statistically 
significant increases in prescribed dosages for the sub-
groups of normal- and high-dose users were observed.
Discussion
In this study, we observed that the prescribed benzo-
diazepine dosages of long-term users did not increase 
over time. This was observed in both incident and 
prevalent long-term users. Furthermore, no increases 
were observed in the subgroups of anxiolytic or hyp-
notic benzodiazepine users. Some differences were 
observed in the comparison of normal- and high-dose 
users. Users of normal doses were older compared with 
users of high doses. This may be a reflection of a pre-
scription policy, whereby older subjects are prescribed 
lower dosages because of a decreased rate of metabo-
lism associated with age. High-dose users more often 
used a combination of anxiolytics and hypnotics and a 
greater percentage of the high-dose users used antide-
pressants compared with the normal-dose users. These 
findings suggest that users of high doses have severer 
psychiatric problems. This is in line with the findings of 
Soumerai, who reported that users of antidepressants 
had a higher risk of dose escalation.17
Comparison with the literature
Our study indicated that, although laboratory studies 
indicated the development of tolerance,11 this aspect 
had no influence on prescribed benzodiazepine dose in 
Table 1 Characteristics of study subjectsa  
Total group of  
benzodiazepine users
Incident long-term  
benzodiazepine users
Prevalent long-term  
benzodiazepine users
P-value
N 1105 113 992 –
Age in years, mean (SD) 64.4 (15.7) 61.1 (18.5) 64.9 (15.3) 0.000
Gender (% female) 72.9 66.4 73.7 0.097
ATC
 % Anxiolytics (N05BA) 47.9 51.3 47.5 0.438
 % Hypnotics (N05CD) 32.2 31.0 32.4 0.765
 % Combination 19.9 17.7 20.2 0.535
Type of benzodiazepineb
 % Diazepam 9.0 12.4 8.6 0.205
 % Oxazepam 20.9 25.7 20.4
 % Temazepam 18.2 19.5 18.0
 % Other 32.0 24.7 32.8
Use of antidepressants (%) 18.7 18.6 18.8 0.966
ATC, anatomical therapeutical codes. 
aAssessment was conducted 6 months after baseline.
bIn users of a single agent, percentages add to 100% with % combination in the table.
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long-term users in clinical practice.2,3,9,11–16 These find-
ings are in line with the results of a study in the USA, 
where no changes in dosage were observed over time 
in a large cohort of benzodiazepine users.17 However, 
we cannot answer the question whether our data indi-
cate that subjects do not ask for dose increases or 
Table 2  Mean benzodiazepine prescription per 3-month period in terms of PDD  
Total group of benzodiazepine users Incident long-term benzodiazepine users Prevalent long-term benzodiazepine users
N 863 56 807
Period
 0–3 months 86.9 (81.5)a 50.8 (49.7) 89.4 (82.7)
 3–6 months 84.5 (75.6) 62.4 (58.6) 86.0 (76.4)
 6–9 months 85.8 (82.2) 63.4 (75.2) 87.3 (82.5)
 9–12 months 86.1 (87.5) 64.0 (114.0) 87.6 (85.2)
 12–15 months 85.1 (88.8) 66.0 (101.3) 86.4 (87.7)
 15–18 months 84.4 (86.0) 58.7 (66.1) 86.2 (86.9)
 18–21 months 87.6 (88.1) 66.2 (70.0) 89.1 (89.0)
 21–24 months 86.6 (85.8) 72.8 (79.9) 87.6 (86.1)
aPDD, mean number of prescribed daily dose per 3 months, SD in parentheses.
Table 3  Linear regression analyses of benzodiazepine dose change 
Regression coefficient (SEM) P-value
Total group of benzodiazepine users 0.034 (0.148) 0.817
Incident long-term benzodiazepine users 0.639 (0.543) 0.240
Prevalent long-term benzodiazepine users –0.008 (0.153) 0.960
Table 4  Comparisons between normal-dose users and high-dose users among prevalent long-term users  
Normal-dose users High-dose users P-value
N 702 105 –
Age in years, mean (SD) 65.3 (14.7) 60.6 (14.2) 0.009
Gender (% female) 74.5 75.2 0.905
ATC
 % Anxiolytics (N05BA) 48.9 40.0 0.095
 % Hypnotics (N05CD) 33.3 21.0 0.013
 % Combination 17.8 39.0 0.000
Type of benzodiazepinea
 % Diazepam 8.8 8.6 0.000
 % Oxazepam 21.8 10.5
 % Temazepam 20.5 0.0
 % Other 31.1 41.9
Half-life periodb
 <24 hours 67.9 67.2 0.889
 ≥24 hours 32.1 32.8
Use of antidepressants (%) 16.7 30.5 0.001
Mean dose, PDD (SD)
 0–3 months 64.0 (37.5) 258.8 (100.9)
 3–6 months 65.7 (45.2) 221.7 (100.5)
 6–9 months 64.7 (46.7) 239.0 (106.5)
 9–12 months 65.2 (48.4) 237.2 (120.5)
 12–15 months 63.7 (46.2) 238.7 (135.6)
 15–18 months 64.0 (47.6) 235.0 (132.6)
 18–21 months 66.6 (52.4) 239.4 (129.1)
 21–24 months 67.1 (54.7) 224.3 (124.9)
ATC, anatomical therapeutical codes.
aIn users of a single agent, percentages add to 100% with % combination in the table.
bData of users of a single benzodiazepine only. 
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whether they reflect the result of a policy of GPs who 
stand firm and do not acknowledge a request for dose 
increases by patients. Some authors hypothesize that 
patients continue to take benzodiazepines mainly to 
compensate for the withdrawal effects and that there 
is a strong placebo component involved in continued 
use.6 On the other hand, the development of toler-
ance differs for the various effects of benzodiazepines. 
It has been suggested that subjects develop complete 
tolerance for sedative–hypnotic effects but only par-
tial tolerance for anxiolytic effects.1616 Therefore, con-
tinued use can also be explained by anxiolytic effects. 
Observational data of the natural course of long-term 
benzodiazepine use until now were scarce and not con-
clusive. Furthermore, various definitions of long-term 
benzodiazepine use make comparisons between stud-
ies difficult.6,17
Strengths and limitations
The strength of this study is that we observed a large 
group of subjects, with a clear definition of long-term 
use and with a sufficient duration of follow-up that was 
adequately monitored by the family practitioner by 3-
month measurements of the prescription data. There 
are some limitations to this study. First, we measured 
the prescription of benzodiazepines by the family 
practitioners and not the actual intake. Patients may have 
received benzodiazepines from sources other than their 
family practitioner. However, in the Netherlands, >90% 
of the benzodiazepine prescriptions are prescribed by 
family practitioners. The remaining 10% is prescribed 
by specialists, mainly psychiatrists in hospitals or other 
institutions. Subjects who solely received prescriptions 
of benzodiazepines by specialists, however, were not 
included in the original family-practice-based study 
(the Benzoredux study). Moreover, in the Dutch health 
care system, subjects are linked to only one family 
practitioner and to one pharmacy. Prescriptions can be 
filled at other pharmacies, but the basic pharmacy of the 
patient is informed and will register the prescription.7,8 
In many countries, there is a street and Internet market 
for benzodiazepines. This involves selling of prescribed 
benzodiazepines, without their taking by the subject 
who received the prescription, or buying of pills on 
the street or over the Internet. Data that describe the 
scale of the street market for benzodiazepines in the 
Netherlands are lacking. As patients included in our 
study have a long-term treatment relationship with 
their family physician, we consider the invalidation 
of our measurements by possible unknown trading of 
benzodiazepines by study subjects to be minor. A blood 
test or urine analysis could have provided us with a more 
valid intake registration. However, because we used the 
data of a former study, we were not able to perform 
these measurements. A  second remark can be made 
concerning the incident long-term benzodiazepine 
users. We knew from the prescription data that they did 
not receive any prescription for benzodiazepines for 6 
months, so we considered them to be benzodiazepine 
starters. These subjects, however, may have used 
benzodiazepines in the time preceding this 6-month 
prescription-free period. Due to the pharmacokinetic 
effects of benzodiazepines, however, earlier intake will 
not have invalidated our data. Another remark can be 
made on the validity of the PDD measurement in the 
first 3-month period in the incident long-term users 
group. The mean number of PDDs is 19% lower in 
this period compared with the second 3-month period. 
Because subjects received the first prescription at some 
time in this period, the cumulative dose (in PDD) 
calculated for these 3 months will be lower due to less 
days of use in this 3-month period compared with the 
following 3-month periods. A final remark concerns the 
validity of the data in time. The data used in this study 
were collected about 10  years earlier. However, the 
effect of the development of tolerance is not related to 
the time period when the observation took place. The 
drugs used 10  years ago do not differ from the main 
agents still prescribed at present.
Conclusion
Our hypothesis was that due to the development of toler-
ance, patients need to increase their benzodiazepine dose 
over time. This study showed that a possible development 
of tolerance does not lead to increased benzodiazepine 
prescription over time in daily practice in the Netherlands.
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